Skip to main content
SpringerLink
Log in

Anti-infectives

New oral HCV drug shows promise

  • Research Highlight
  • Published:

From Nature Reviews Microbiology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

ORIGINAL RESEARCH PAPER

  1. Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96–100 (2010)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

FURTHER READING

  1. O'Boyle II, D. R. et al. Development of a cell-based high-throughput specificity screen using a hepatitis C virus–bovine viral diarrhea virus dual replicon assay. Antimicrob. Agents Chemother. 49, 1346–1353 (2005)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lemm, J. A. et al. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 84, 482–491 (2010)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Locum Assistant Editor, Nature Reviews Drug Discovery,

    Man Tsuey Tse

Authors
  1. Man Tsuey Tse
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tse, M. New oral HCV drug shows promise. Nat Rev Microbiol 8, 464–465 (2010). https://doi.org/10.1038/nrmicro2396

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrmicro2396

  • Springer Nature Limited

Search

Navigation